[go: up one dir, main page]

MX2011011058A - Antagonistas del receptor ep4 para el tratamiento de cancer. - Google Patents

Antagonistas del receptor ep4 para el tratamiento de cancer.

Info

Publication number
MX2011011058A
MX2011011058A MX2011011058A MX2011011058A MX2011011058A MX 2011011058 A MX2011011058 A MX 2011011058A MX 2011011058 A MX2011011058 A MX 2011011058A MX 2011011058 A MX2011011058 A MX 2011011058A MX 2011011058 A MX2011011058 A MX 2011011058A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
compound
selective
pharmaceutically acceptable
Prior art date
Application number
MX2011011058A
Other languages
English (en)
Other versions
MX345032B (es
Inventor
Yukinori Take
Shinichi Koizumi
Takako Okumura
Kazuhiko Nonomura
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of MX2011011058A publication Critical patent/MX2011011058A/es
Publication of MX345032B publication Critical patent/MX345032B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención provee un medicamento para el tratamiento de cáncer, el cual causa una reducción del cáncer. Esta invención se relaciona con el uso de un compuesto el cual tiene actividades inhibidoras en contra el receptor de prostaglandina E2 (receptor EP4) y es representado por la siguiente formula general (I), (II), (III), o (IV), o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal para la fabricación de un medicamento para el tratamiento de cáncer. La invención se relaciona con un método para el tratamiento de cáncer que comprende administrar el compuesto o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal a humanos o animales. El compuesto o una sal farmacéuticamente aceptable de éste, o la composición farmacéutica pueden ser usadas en combinación con uno o más agentes activos secundarios. (ver fórmulas).
MX2011011058A 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer. MX345032B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009104568 2009-04-22
JP2010015445 2010-01-27
PCT/JP2010/057114 WO2010123049A1 (ja) 2009-04-22 2010-04-22 癌治療のための選択的ｅｐ４受容体拮抗物質

Publications (2)

Publication Number Publication Date
MX2011011058A true MX2011011058A (es) 2011-11-18
MX345032B MX345032B (es) 2017-01-12

Family

ID=43011165

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008394A MX369117B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2011011058A MX345032B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016008394A MX369117B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer.

Country Status (11)

Country Link
US (5) US8921391B2 (es)
EP (3) EP3431085B1 (es)
JP (1) JP5668219B2 (es)
KR (1) KR101575706B1 (es)
CN (2) CN105596320B (es)
BR (1) BRPI1014174B8 (es)
CA (1) CA2754702C (es)
ES (3) ES2562814T3 (es)
MX (2) MX369117B (es)
RU (1) RU2563817C2 (es)
WO (1) WO2010123049A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5668219B2 (ja) * 2009-04-22 2015-02-12 ラクオリア創薬株式会社 癌治療のための選択的ｅｐ４受容体拮抗物質
KR102535283B1 (ko) * 2014-05-23 2023-05-22 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료를 위한 조합 요법
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
AU2019255196A1 (en) * 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
JP2021530487A (ja) * 2018-07-11 2021-11-11 アリーズ セラピューティクス， インコーポレイテッド Ｅｐ４阻害剤およびその合成
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
CN113260363A (zh) * 2018-09-27 2021-08-13 阿瑞斯医疗有限公司 格拉普兰特(grapiprant)单位剂型
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
CN114206866A (zh) * 2019-06-11 2022-03-18 泰昂治疗公司 前列腺素e2受体4拮抗剂及其用途
GB201914585D0 (en) 2019-10-09 2019-11-20 Heptares Therapeutics Ltd Prostaglandin ep4 receptor antagonist compounds
CN119657828B (zh) * 2024-11-12 2025-11-14 北京航空材料研究院股份有限公司 一种带多角度管腔型壳的制备方法及模具
CN119634669B (zh) * 2024-11-12 2025-11-14 北京航空材料研究院股份有限公司 含有多角度管腔的蜡模制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054808A1 (fr) * 1999-03-16 2000-09-21 Toray Industries, Inc. Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
ATE272398T1 (de) 1999-08-10 2004-08-15 Glaxo Group Ltd Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
EP1258473A4 (en) * 2000-02-22 2004-09-01 Ono Pharmaceutical Co BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
WO2003086390A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
RU2004133347A (ru) 2002-04-16 2005-05-10 Фудзисава Фармасьютикал Ко.,Лтд. (Jp) Лекарственное средство для профилактики и/или лечения хронического отторжения
MXPA06002551A (es) 2003-09-03 2006-06-20 Pfizer Compuestos de aril o heteroaril amida.
CN1946391A (zh) * 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
EA200601847A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Замещённые метиларил- или гетероариламидные соединения
CN101137656B (zh) 2005-03-11 2010-12-22 拉夸里亚创药株式会社 咪唑衍生物的晶型
JP5289046B2 (ja) 2005-05-19 2013-09-11 メルク カナダ インコーポレイテッド Ｅｐ４アンタゴニストとしてのキノリン誘導体
JP5668219B2 (ja) 2009-04-22 2015-02-12 ラクオリア創薬株式会社 癌治療のための選択的ｅｐ４受容体拮抗物質
KR101539436B1 (ko) 2013-12-30 2015-07-24 주식회사 효성 가스 절연 개폐기의 부분 방전 검출 장치

Also Published As

Publication number Publication date
HK1214763A1 (en) 2016-08-05
ES2960438T3 (es) 2024-03-04
US20170253595A1 (en) 2017-09-07
MX345032B (es) 2017-01-12
EP3431085C0 (en) 2023-10-11
JPWO2010123049A1 (ja) 2012-10-25
ES2562814T3 (es) 2016-03-08
US20150111920A1 (en) 2015-04-23
US20200188367A1 (en) 2020-06-18
CN105596320B (zh) 2019-03-22
CN105596320A (zh) 2016-05-25
CA2754702C (en) 2016-06-07
JP5668219B2 (ja) 2015-02-12
WO2010123049A1 (ja) 2010-10-28
BRPI1014174B1 (pt) 2020-10-06
CN102421429B (zh) 2016-08-17
ES2698508T3 (es) 2019-02-05
RU2563817C2 (ru) 2015-09-20
EP3431085A1 (en) 2019-01-23
US20220073510A1 (en) 2022-03-10
US8921391B2 (en) 2014-12-30
KR101575706B1 (ko) 2015-12-10
EP2965756B1 (en) 2018-10-10
EP2422779A1 (en) 2012-02-29
US20120088723A1 (en) 2012-04-12
BRPI1014174A2 (pt) 2016-04-05
EP2422779B1 (en) 2016-01-06
KR20120096402A (ko) 2012-08-30
HK1166700A1 (en) 2012-11-09
US10611761B2 (en) 2020-04-07
CN102421429A (zh) 2012-04-18
US9688674B2 (en) 2017-06-27
US11840530B2 (en) 2023-12-12
BRPI1014174B8 (pt) 2021-05-25
CA2754702A1 (en) 2010-10-28
EP2422779A4 (en) 2013-06-19
EP3431085B1 (en) 2023-10-11
EP2965756A1 (en) 2016-01-13
MX369117B (es) 2019-10-28
US10947235B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
UY32045A (es) Compuesto amida
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
DK201470535A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
UY32062A (es) Inhibidores de beta-secretasa
EA201170473A1 (ru) Морфинановые соединения
BR112012023021A2 (pt) compostos de indazol e seus usos
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
GT201200164A (es) "nuevos compuestos de espiropiperidina"
DOP2011000260A (es) Pirimidinas fusionadas
UY32238A (es) Agonistas de los receptores de la melanocortina
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
MX2011009847A (es) Agentes antihelminticos y su uso.
MX2016013908A (es) Novedoso compuesto de 1,2,4-triazina disustituida.
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CL2011001050A1 (es) Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros.
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico

Legal Events

Date Code Title Description
FG Grant or registration